rosiglitazone has been researched along with lactic acid in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Berrebi-Bertrand, I; Bril, A; Buckingham, RE; Delerive, P; Khandoudi, N; Staels, B | 1 |
| Derlacz, RA; Drozak, J; Hyc, K; Jagielski, AK; Jarzyna, R; Usarek, M | 1 |
| Bao, Y; Jia, W; Qiu, Y; Su, M; Wang, X; Zhao, T | 1 |
| Ala-Korpela, M; Badeau, RM; Honka, MJ; Kangas, AJ; Lautamäki, R; Nuutila, P; Soininen, P; Stewart, M | 1 |
| Camberos, MC; Cigorraga, SB; Galardo, MN; Gorga, A; Meroni, SB; Pellizzari, EH; Regueira, M; Riera, MF; Rindone, GM | 1 |
| Constantin-Teodosiu, D; Crossland, H; Gardiner, SM; Greenhaff, PL | 1 |
| Kuranaga, T; Ono, Y; Sato, Y; Takatsuki, S; Unno, Y; Wakimoto, T; Yamamoto, H; Yazawa, K | 1 |
1 trial(s) available for rosiglitazone and lactic acid
| Article | Year |
|---|---|
Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glutamine; Humans; Hypoglycemic Agents; Lactic Acid; Lipoproteins; Male; Middle Aged; Myocardium; PPAR gamma; Rosiglitazone; Thiazolidinediones; Time Factors | 2014 |
7 other study(ies) available for rosiglitazone and lactic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.
Topics: Animals; Cardiotonic Agents; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Lactic Acid; Male; Mitogen-Activated Protein Kinases; Monosaccharide Transport Proteins; Muscle Proteins; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cells, Cultured; Gluconeogenesis; Glucose; Hepatocytes; Humans; Hypoglycemic Agents; Kidney Cortex; Kidney Tubules; Lactic Acid; Male; Phosphoenolpyruvate Carboxykinase (GTP); PPAR gamma; Rabbits; Rosiglitazone; Thiazolidinediones; Trimethoprim | 2008 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.
Topics: Carbamates; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Agents; Lactic Acid; Lysine; Metabolomics; Metformin; Piperidines; Rosiglitazone; Thiazolidinediones; Uric Acid; Valine | 2009 |
PPARγ activation regulates lipid droplet formation and lactate production in rat Sertoli cells.
Topics: Animals; Glucose; L-Lactate Dehydrogenase; Lactic Acid; Lipid Droplets; Lipid Metabolism; Male; Models, Biological; PPAR gamma; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Sertoli Cells; Triglycerides | 2017 |
Peroxisome proliferator-activated receptor γ agonism attenuates endotoxaemia-induced muscle protein loss and lactate accumulation in rats.
Topics: Animals; Drug Evaluation, Preclinical; Endotoxemia; Gene Expression Regulation; Interleukin-6; Lactic Acid; Male; Muscle Proteins; Muscle, Skeletal; PPAR gamma; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2017 |
Palmitoyl lactic acid induces adipogenesis and a brown fat-like phenotype in 3T3-L1 preadipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adipose Tissue, Brown; Animals; Cell Differentiation; Lactic Acid; Lipid Droplets; Mice; Obesity; Palmitates; Phenotype; Pioglitazone; PPAR gamma; Rosiglitazone | 2018 |